3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1/2
2
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hematologic Diseases
1
Interventions
Cisplatin
187
Carboplatin
182
Paclitaxel
177
Docetaxel
145
Cyclophosphamide
129
Dexamethasone
117
pembrolizumab
106
Doxorubicin
103
Bevacizumab
103
Gemcitabine
102
Rituximab
96
Prednisone
87
Fluorouracil
86
Pemetrexed
82
Radiotherapy
77
Vincristine
71
Etoposide
71
Capecitabine
69
Nivolumab
68
Trastuzumab
67
Leucovorin
64
Cytarabine
57
Methotrexate
52
Oxaliplatin
49
atezolizumab
48
Lenalidomide
43
Ipilimumab
40
Filgrastim
40
Bortezomib
39
Sorafenib
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Has results
×
vosaroxin
×
Clear all
NCT01191801
2018-08-22
VALOR
Sunesis Pharmaceuticals
Phase 3
Completed
711 enrolled
15 charts